+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NASH Biomarkers (Non alcoholic Steatohepatitis) Market Size, Outlook and Growth Opportunities, 2019- 2025

  • ID: 4859006
  • Report
  • November 2019
  • Region: Global
  • 130 pages
  • OG Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • GENFIT SA
  • Gilead Sciences
  • Novartis AG
  • MORE
Global NASH Biomarkers (Non alcoholic Steatohepatitis) Market size, Outlook and Opportunities 2019- 2025: By Type (Hepatic fibrosis biomarkers, Apoptosis biomarkers, Oxidative stress biomarkers, Serum biomarkers and Other biomarkers), By End User (Hospitals, Diagnostic labs, Pharma & CRO industry and Academic research institutes) and By Region

The 'NASH Biomarkers (Non alcoholic Steatohepatitis) market outlook to 2025' report includes the latest predictions of the global NASH Biomarkers (Non alcoholic Steatohepatitis) market along with geography, therapy area, and applications. The report specifically focuses on different types of NASH Biomarkers (Non alcoholic Steatohepatitis) with special attention to their emergence over the forecast period to 2025.

The research report provides objective measures to tap into future opportunities that will be available over the next six-years. It also highlights key areas to watch over the future along with detailed insights into drivers and challenges across different NASH Biomarkers (Non alcoholic Steatohepatitis) applications and products.

The NASH Biomarkers (Non alcoholic Steatohepatitis) market report aggregates the current market size based on volume and average price data. It also includes a six-year outlook to 2025 based on anticipated growth rates for each sub-segment and industry as a whole.

The base case outlook in the next six-years for different types of NASH Biomarkers (Non alcoholic Steatohepatitis), across different verticals and countries, is provided. It additionally examines the key dynamics around companies, markets, along with key trends, drivers and challenges facing the NASH Biomarkers (Non alcoholic Steatohepatitis) worldwide.

The report covers a broad region from the Asia Pacific, North America, Europe, Latin America, and Middle East Africa from 2018 to 2025. 12 countries across these regions are analyzed independently in the NASH Biomarkers (Non alcoholic Steatohepatitis) report. Impact of domestic market conditions, price variations, competition, government policies, healthcare spending, technological and local market conditions are assessed for country-level forecasts.

Global spending on healthcare continues to increase significantly with the aging population, increased access to treatment and ongoing advancements in technology. This provides strong support for NASH Biomarkers (Non alcoholic Steatohepatitis) market growth in the medium to long term future. While growth will remain steady in the developed markets, Asian and other emerging markets will be key for NASH Biomarkers (Non alcoholic Steatohepatitis) market growth from 2019 to 2025.

To address the expanding need for advanced NASH Biomarkers (Non alcoholic Steatohepatitis) products, companies are rapidly embracing the new market dynamics, primarily focusing on new launches, specifically to suit local and regional demand patterns. Accordingly, detailed discussion about broader implications of key strategies, product launches, and other latest NASH Biomarkers (Non alcoholic Steatohepatitis) market developments are included in the research work.

Scope of the NASH Biomarkers (Non alcoholic Steatohepatitis) report
This report covers the 2018 market scenario and outlook of NASH Biomarkers (Non alcoholic Steatohepatitis) to 2025. Market size is computed using different types, applications of NASH Biomarkers (Non alcoholic Steatohepatitis) across geographies.

1. NASH Biomarkers (Non alcoholic Steatohepatitis) market size, US$, 2018-2025
2. NASH Biomarkers (Non alcoholic Steatohepatitis) market drivers
3. NASH Biomarkers (Non alcoholic Steatohepatitis) market challenges
4. NASH Biomarkers (Non alcoholic Steatohepatitis) market opportunities
5. NASH Biomarkers (Non alcoholic Steatohepatitis) market trends
6. NASH Biomarkers (Non alcoholic Steatohepatitis) market size forecast by type, 2018-2025
7. NASH Biomarkers (Non alcoholic Steatohepatitis) market size forecast by application, 2018-2025
8. NASH Biomarkers (Non alcoholic Steatohepatitis) market size forecast by country, 2018-2025
9. NASH Biomarkers (Non alcoholic Steatohepatitis) market companies and their strategies
10. Financial and Business Profile of leading vendors
11. NASH Biomarkers (Non alcoholic Steatohepatitis) market news and deals

The unbiased independent analysis can save clients significant time and expense by providing an intensive evaluation of NASH Biomarkers (Non alcoholic Steatohepatitis) market conditions. Our intensive research and sophisticated forecast methodology ensure the reliability of market estimates. Further, one free hour of our analyst’s time can be provided upon the procurement of this market report.

The report will be delivered in two working days after order confirmation.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • GENFIT SA
  • Gilead Sciences
  • Novartis AG
  • MORE
1. Table of Contents
1.1. List of Tables
1.2. List of Figures

2. A Review of 2018. and Outlook to 2025
2.1. Trend Analysis
2.2. Critical Success Factors
2.3. Demand and Growth Dynamics by Type
2.4. Demand and Growth Dynamics by Application
2.5. Demand and Growth Dynamics by Market

3. Strategic Analysis
3.1. Largest Drivers of NASH Biomarkers (Non alcoholic Steatohepatitis) Market Growth
3.2. Different Challenges Faced by NASH Biomarkers (Non alcoholic Steatohepatitis) Companies
3.3. Five Forces Analysis

4. NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook By Type
4.1 Hepatic fibrosis biomarkers
4.2 Apoptosis biomarkers
4.3 Oxidative stress biomarkers
4.4 Serum biomarkers
4.5 Other biomarkers

5. NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook By End User
5.1 Hospitals
5.2 Diagnostic labs
5.3 Pharma & CRO industry
5.4 Inhaler technology

6 Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook
6.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Asia Pacific market
6.2 Top Applications contributing to Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis)
6.3 Top countries contributing to Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis)

7. Europe NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook
7.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Europe market
7.2 Top Applications contributing to Europe NASH Biomarkers (Non alcoholic Steatohepatitis)
7.3 Top countries contributing to Europe NASH Biomarkers (Non alcoholic Steatohepatitis)

8. North America NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook
8.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to North America market
8.2 Top Applications contributing to North America NASH Biomarkers (Non alcoholic Steatohepatitis)
8.3 Top countries contributing to North America NASH Biomarkers (Non alcoholic Steatohepatitis)

9. South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook
9.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to South and Central America market
9.2 Top Applications contributing to South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis)
9.3 Top countries contributing to South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis)

10 Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis) Market Outlook
10.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Middle East Africa market
10.2 Top Applications contributing to Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis)
10.3 Top countries contributing to Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis)

11 Company Profile Snapshots
11.1 Top Companies Operating in NASH Biomarkers (Non alcoholic Steatohepatitis) market
11.2 Allergan Plc Business Profile, SWOT and Financial Analysis
11.3 AstraZeneca Business Profile, SWOT and Financial Analysis
11.4 Boehringer Ingelheim Business Profile, SWOT and Financial Analysis
11.5 Bristol-Myers Squibb Company Business Profile, SWOT and Financial Analysis
11.6 GENFIT SA Business Profile, SWOT and Financial Analysis
11.7. Gilead Sciences Business Profile, SWOT and Financial Analysis
11.8. Novartis AG Business Profile, SWOT and Financial Analysis
11.9. Novo Nordisk A/S Business Profile, SWOT and Financial Analysis
11.10 Prometheus Laboratories Corp. Business Profile, SWOT and Financial Analysis
11.11 Pfizer Inc. Business Profile, SWOT and Financial Analysis

12 Recent Industry Developments

13 Appendix
13.1 Author's Expertise
13.2 Sources and Methodology
13.3 Contacts
Note: Product cover images may vary from those shown
  • Allergan Plc
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • GENFIT SA
  • Gilead Sciences
  • Novartis AG
  • Novo Nordisk A/S
  • Prometheus Laboratories Corp.
  • Pfizer Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll